SCHEDULE 13G/A: Forbion Entities Maintain Significant Stake in Replimune Group, Disclosing 6.1% Beneficial Ownership

Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. have filed an amended Schedule 13G, reporting a continued beneficial ownership of 6.1% in Replimune Group, Inc.'s common stock as of December 31, 2024.

Summary

• Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. (collectively, "Reporting Persons") have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership in REPLIMUNE GROUP, INC.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 4,219,340 shares of Replimune Group, Inc. Common Stock.
• This ownership represents 6.1% of the Issuer's outstanding Common Stock.
• The total beneficially owned shares include 3,970,668 shares of Common Stock and an additional 248,672 shares issuable upon the exercise of warrants.
• The percentage of class is calculated based on 68,417,444 outstanding shares reported by Replimune Group, Inc. in its Form 10-Q filed on November 12, 2024, plus the 248,672 shares underlying warrants held by the Reporting Persons.
• Both Forbion III COOP and Forbion III Management B.V. are organized under the laws of the Netherlands and share voting and dispositive power over the reported shares.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the company itself.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the Issuer's future outlook.

Industry Context

This Schedule 13G filing indicates a significant, continued institutional investment in Replimune Group, Inc., a biotechnology company. Such filings are standard disclosures for investors holding more than 5% of a company's stock, providing transparency on major ownership stakes within the biotech sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and liquidity.

Key Dates

Keywords

REPLIMUNE GROUP INC, Forbion Capital Fund III Cooperatief U.A., Forbion III Management B.V., Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Biotechnology Investment, Institutional Ownership